NEW YORK, July 3 – The pharmacogenomics market is expected to grow to more than $6 billion by 2005, compared with $1.7 billion in 2000, consulting firm Frost & Sullivan said Tuesday in a report.

The figures for the pharmacogenomics market reflect actual and anticipated revenues stemming from services, gene-based diagnostics, and orphan drugs.

Yet, despite the strong growth outlook, Frost & Sullivan said that ethical debates could put a damper on growth, particularly in diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.